Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Jingyou Yu; Paul V Thomas; Michaela Sciacca; Cindy Wu; Jinyan Liu; Xuan He; Jessica Miller; Nicole P Hachmann; Nehalee Surve; Katherine McMahan; Catherine Jacob-Dolan; Olivia Powers; Kevin Hall; Julia Barrett; David Hope; Camille R Mazurek; Tetyana Murdza; William C Chang; Emily Golub; Phyllis A Rees; Caroline E Peterson; Agnes Hajduczki; Wei-Hung Chen; Elizabeth J Martinez; Elizabeth Hussin; Camille Lange; Hua Gong; Gary R Matyas; Mangala Rao; Mehul Suthar; Mona Boursiquot; Anthony Cook; Laurent Pessaint; Mark G Lewis; Hanne Andersen; Diane L Bolton; Nelson L Michael; M Gordon Joyce; Kayvon Modjarrad; Dan H Barouch

doi:10.1016/j.xcrm.2023.101018

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Cell Rep Med. 2023 Apr 18;4(4):101018. doi: 10.1016/j.xcrm.2023.101018. Epub 2023 Mar 27.

Authors

Jingyou Yu¹, Paul V Thomas², Michaela Sciacca¹, Cindy Wu¹, Jinyan Liu¹, Xuan He¹, Jessica Miller¹, Nicole P Hachmann¹, Nehalee Surve¹, Katherine McMahan¹, Catherine Jacob-Dolan³, Olivia Powers¹, Kevin Hall¹, Julia Barrett¹, David Hope¹, Camille R Mazurek¹, Tetyana Murdza¹, William C Chang⁴, Emily Golub², Phyllis A Rees², Caroline E Peterson², Agnes Hajduczki², Wei-Hung Chen², Elizabeth J Martinez², Elizabeth Hussin², Camille Lange², Hua Gong⁵, Gary R Matyas⁵, Mangala Rao⁵, Mehul Suthar⁶, Mona Boursiquot⁷, Anthony Cook⁷, Laurent Pessaint⁷, Mark G Lewis⁷, Hanne Andersen⁷, Diane L Bolton⁸, Nelson L Michael⁹, M Gordon Joyce¹⁰, Kayvon Modjarrad⁴, Dan H Barouch¹¹

Affiliations

¹ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
² Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
³ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
⁴ Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.
⁵ U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
⁶ Emory University, Atlanta, GA, USA.
⁷ Bioqual, Rockville, MD, USA.
⁸ Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
⁹ Center for Infectious Diseases Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD 20910, USA.
¹⁰ Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. Electronic address: gjoyce@eidresearch.org.
¹¹ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: dbarouch@bidmc.harvard.edu.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.

Keywords: B cell; BA.5; Omicron; SARS-CoV-2; T cell; antibody; macaque; vaccine.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Ad26COVS1
Animals
COVID-19* / prevention & control
Ferritins
Humans
Macaca
Nanoparticles*
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Vaccines*

Substances

spike protein, SARS-CoV-2
Ad26COVS1
Spike Glycoprotein, Coronavirus
Ferritins
Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding